TY - JOUR
T1 - The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse
AU - Lee, Hyoung Gon
AU - Casadesus, Gemma
AU - Nunomura, Akihiko
AU - Zhu, Xiongwei
AU - Castellani, Rudy J.
AU - Richardson, Sandy L.
AU - Perry, George
AU - Felsher, Dean W.
AU - Petersen, Robert B.
AU - Smith, Mark A.
N1 - Funding Information:
Supported by the National Institutes of Health (grants AG031364, AG030096 and AG028679 ) and Alzheimer's Association ( NIRG-07-60164 ).
Funding Information:
M.A.S. is, or has in the past been, a paid consultant for, owns equity or stock options in, and/or receives grant funding from Neurotez, Neuropharm, Edenland, Panacea Pharmaceuticals, and Voyager Pharmaceuticals. G.P. is a paid consultant for and/or owns equity or stock options in Takeda Pharmaceuticals, Voyager Pharmaceuticals, Panacea Pharmaceuticals, and Neurotez Pharmaceuticals.
PY - 2009/3
Y1 - 2009/3
N2 - Many different proteins associated with the cell cycle, including cyclins, cyclin-dependent kinases, and proto-oncogenes such as c-MYC (MYC), are increased in degenerating neurons. Consequently, an ectopic activation of the cell cycle machinery in neurons has emerged as a potential pathogenic mechanism of neuronal dysfunction and death in many neurodegenerative diseases, including Alzheimer's disease. However, the exact role of cell cycle re-entry during disease pathogenesis is unclear, primarily because of the lack of relevant research models to study the effects of cell cycle re-entry on mature neurons in vivo. To address this issue, we developed a new transgenic mouse model in which forebrain neurons (CaMKII-MYC) can be induced to enter the cell cycle using the physiologically relevant proto-oncogene MYC to drive cell cycle re-entry. We show that such cell cycle re-entry results in neuronal cell death, gliosis, and cognitive deficits. These findings provide compelling evidence that dysregulation of cell cycle re-entry results in neurodegeneration in vivo. Our current findings, coupled with those of previous reports, strengthen the hypothesis that neurodegeneration in Alzheimer's disease, similar to cellular proliferation in cancer, is a disease that results from inappropriate cell cycle control.
AB - Many different proteins associated with the cell cycle, including cyclins, cyclin-dependent kinases, and proto-oncogenes such as c-MYC (MYC), are increased in degenerating neurons. Consequently, an ectopic activation of the cell cycle machinery in neurons has emerged as a potential pathogenic mechanism of neuronal dysfunction and death in many neurodegenerative diseases, including Alzheimer's disease. However, the exact role of cell cycle re-entry during disease pathogenesis is unclear, primarily because of the lack of relevant research models to study the effects of cell cycle re-entry on mature neurons in vivo. To address this issue, we developed a new transgenic mouse model in which forebrain neurons (CaMKII-MYC) can be induced to enter the cell cycle using the physiologically relevant proto-oncogene MYC to drive cell cycle re-entry. We show that such cell cycle re-entry results in neuronal cell death, gliosis, and cognitive deficits. These findings provide compelling evidence that dysregulation of cell cycle re-entry results in neurodegeneration in vivo. Our current findings, coupled with those of previous reports, strengthen the hypothesis that neurodegeneration in Alzheimer's disease, similar to cellular proliferation in cancer, is a disease that results from inappropriate cell cycle control.
UR - http://www.scopus.com/inward/record.url?scp=62549114846&partnerID=8YFLogxK
U2 - 10.2353/ajpath.2009.080583
DO - 10.2353/ajpath.2009.080583
M3 - Article
C2 - 19164506
AN - SCOPUS:62549114846
VL - 174
SP - 891
EP - 897
JO - American Journal of Pathology
JF - American Journal of Pathology
SN - 0002-9440
IS - 3
ER -